🚀 VC round data is live in beta, check it out!
PharmX Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for PharmX Technologies and similar public comparables like MeVis, Mach7 Technologies, SOFTMAX, BIT Computer and more.
PharmX Technologies Overview
About PharmX Technologies
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
Founded
1950
HQ
Employees
109
Website
Financials (FY)
EV
$48M
PharmX Technologies Financials
PharmX Technologies reported last fiscal year revenue of $5M and EBITDA of $996K.
In the same fiscal year, PharmX Technologies generated $4M in gross profit, $996K in EBITDA, and had net loss of ($189K).
Revenue (LTM)
PharmX Technologies P&L
In the most recent fiscal year, PharmX Technologies reported revenue of $5M and EBITDA of $996K.
PharmX Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 81% | XXX | XXX | XXX |
| EBITDA | — | XXX | $996K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (19%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($189K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (4%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PharmX Technologies Stock Performance
PharmX Technologies has current market cap of $50M, and enterprise value of $48M.
Market Cap Evolution
PharmX Technologies' stock price is $0.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $48M | $50M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmX Technologies Valuation Multiples
PharmX Technologies trades at 9.1x EV/Revenue multiple, and 48.0x EV/EBITDA.
EV / Revenue (LTM)
PharmX Technologies Financial Valuation Multiples
As of April 20, 2026, PharmX Technologies has market cap of $50M and EV of $48M.
Equity research analysts estimate PharmX Technologies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmX Technologies has a P/E ratio of (261.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50M | XXX | $50M | XXX | XXX | XXX |
| EV (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 48.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (46.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.2x | XXX | XXX | XXX |
| P/E | — | XXX | (261.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PharmX Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PharmX Technologies Margins & Growth Rates
PharmX Technologies' revenue in the last fiscal year grew by 6%.
PharmX Technologies' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
PharmX Technologies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (2%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 69% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | (4%) | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 101% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PharmX Technologies Public Comps
See public comps and valuation multiples for other EHR & Practice Management and Healthcare Software comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PharmX Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| MeVis | XXX | XXX | XXX | XXX | XXX | XXX |
| Mach7 Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| SOFTMAX | XXX | XXX | XXX | XXX | XXX | XXX |
| BIT Computer | XXX | XXX | XXX | XXX | XXX | XXX |
| SMAIO | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmX Technologies M&A Activity
PharmX Technologies acquired XXX companies to date.
Last acquisition by PharmX Technologies was on XXXXXXXX, XXXXX. PharmX Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PharmX Technologies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharmX Technologies Investment Activity
PharmX Technologies invested in XXX companies to date.
PharmX Technologies made its latest investment on XXXXXXXX, XXXXX. PharmX Technologies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PharmX Technologies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PharmX Technologies
| When was PharmX Technologies founded? | PharmX Technologies was founded in 1950. |
| Where is PharmX Technologies headquartered? | PharmX Technologies is headquartered in Australia. |
| How many employees does PharmX Technologies have? | As of today, PharmX Technologies has over 109 employees. |
| Is PharmX Technologies publicly listed? | Yes, PharmX Technologies is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of PharmX Technologies? | PharmX Technologies trades under PHX ticker. |
| When did PharmX Technologies go public? | PharmX Technologies went public in 1973. |
| Who are competitors of PharmX Technologies? | PharmX Technologies main competitors are MeVis, Mach7 Technologies, SOFTMAX, BIT Computer. |
| What is the current market cap of PharmX Technologies? | PharmX Technologies' current market cap is $50M. |
| What is the current revenue of PharmX Technologies? | PharmX Technologies' last fiscal year revenue is $5M. |
| What is the current EV/Revenue multiple of PharmX Technologies? | Current revenue multiple of PharmX Technologies is 9.1x. |
| Is PharmX Technologies profitable? | No, PharmX Technologies is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.